381 related articles for article (PubMed ID: 25897204)
21. Current and emerging treatments and surgical interventions for Morquio A syndrome: a review.
Tomatsu S; Mackenzie WG; Theroux MC; Mason RW; Thacker MM; Shaffer TH; Montaño AM; Rowan D; Sly W; Alméciga-Díaz CJ; Barrera LA; Chinen Y; Yasuda E; Ruhnke K; Suzuki Y; Orii T
Res Rep Endocr Disord; 2012 Dec; 2012(2):65-77. PubMed ID: 24839594
[TBL] [Abstract][Full Text] [Related]
22. Molecular genetics and metabolism, special edition: Diagnosis, diagnosis and prognosis of Mucopolysaccharidosis IVA.
Peracha H; Sawamoto K; Averill L; Kecskemethy H; Theroux M; Thacker M; Nagao K; Pizarro C; Mackenzie W; Kobayashi H; Yamaguchi S; Suzuki Y; Orii K; Orii T; Fukao T; Tomatsu S
Mol Genet Metab; 2018 Sep; 125(1-2):18-37. PubMed ID: 29779902
[TBL] [Abstract][Full Text] [Related]
23. Enhancement of drug delivery: enzyme-replacement therapy for murine Morquio A syndrome.
Tomatsu S; Montaño AM; Dung VC; Ohashi A; Oikawa H; Oguma T; Orii T; Barrera L; Sly WS
Mol Ther; 2010 Jun; 18(6):1094-102. PubMed ID: 20332769
[TBL] [Abstract][Full Text] [Related]
24. Bone Growth Induction in Mucopolysaccharidosis IVA Mouse.
Rintz E; Herreño-Pachón AM; Celik B; Nidhi F; Khan S; Benincore-Flórez E; Tomatsu S
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373036
[TBL] [Abstract][Full Text] [Related]
25. [Mucopolysaccharidosis IVA (Morquio A syndrome): clinical, biological and therapeutic aspects].
Bouzidi H; Khedhiri S; Laradi S; Ferchichi S; Daudon M; Miled A
Ann Biol Clin (Paris); 2007; 65(1):5-11. PubMed ID: 17264033
[TBL] [Abstract][Full Text] [Related]
26. Diagnostic journey and impact of enzyme replacement therapy for mucopolysaccharidosis IVA: a sibling control study.
Ficicioglu C; Matalon DR; Luongo N; Menello C; Kornafel T; Degnan AJ
Orphanet J Rare Dis; 2020 Nov; 15(1):336. PubMed ID: 33256811
[TBL] [Abstract][Full Text] [Related]
27. Mucopolysaccharidosis IVA and glycosaminoglycans.
Khan S; Alméciga-Díaz CJ; Sawamoto K; Mackenzie WG; Theroux MC; Pizarro C; Mason RW; Orii T; Tomatsu S
Mol Genet Metab; 2017; 120(1-2):78-95. PubMed ID: 27979613
[TBL] [Abstract][Full Text] [Related]
28. Elosulfase Alfa: a review of its use in patients with mucopolysaccharidosis type IVA (Morquio A syndrome).
Lyseng-Williamson KA
BioDrugs; 2014 Oct; 28(5):465-75. PubMed ID: 25200032
[TBL] [Abstract][Full Text] [Related]
29. Activity of daily living for Morquio A syndrome.
Yasuda E; Suzuki Y; Shimada T; Sawamoto K; Mackenzie WG; Theroux MC; Pizarro C; Xie L; Miller F; Rahman T; Kecskemethy HH; Nagao K; Morlet T; Shaffer TH; Chinen Y; Yabe H; Tanaka A; Shintaku H; Orii KE; Orii KO; Mason RW; Montaño AM; Fukao T; Orii T; Tomatsu S
Mol Genet Metab; 2016 Jun; 118(2):111-22. PubMed ID: 27161890
[TBL] [Abstract][Full Text] [Related]
30. Enzyme replacement therapy interruption in mucopolysaccharidosis type IVA patients and its impact in different clinical outcomes.
Politei J; Porras-Hurtado GL; Guelbert N; Fainboim A; Horovitz DDG; Satizábal JM
JIMD Rep; 2021 Mar; 58(1):104-113. PubMed ID: 33728253
[TBL] [Abstract][Full Text] [Related]
31. Proteomic Analysis in Morquio A Cells Treated with Immobilized Enzymatic Replacement Therapy on Nanostructured Lipid Systems.
Álvarez JV; Bravo SB; García-Vence M; De Castro MJ; Luzardo A; Colón C; Tomatsu S; Otero-Espinar FJ; Couce ML
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31540344
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of Intravenous Elosulfase Alfa for Mucopolysaccharidosis Type IVA: A Systematic Review and Meta-Analysis.
Lee CL; Chuang CK; Syu YM; Chiu HC; Tu YR; Lo YT; Chang YH; Lin HY; Lin SP
J Pers Med; 2022 Aug; 12(8):. PubMed ID: 36013287
[TBL] [Abstract][Full Text] [Related]
33. Review of clinical presentation and diagnosis of mucopolysaccharidosis IVA.
Hendriksz CJ; Harmatz P; Beck M; Jones S; Wood T; Lachman R; Gravance CG; Orii T; Tomatsu S
Mol Genet Metab; 2013; 110(1-2):54-64. PubMed ID: 23665161
[TBL] [Abstract][Full Text] [Related]
34. Effect of enzyme replacement therapy on the growth of patients with Morquio A.
Doherty C; Stapleton M; Piechnik M; Mason RW; Mackenzie WG; Yamaguchi S; Kobayashi H; Suzuki Y; Tomatsu S
J Hum Genet; 2019 Jul; 64(7):625-635. PubMed ID: 31019230
[TBL] [Abstract][Full Text] [Related]
35. Oxidative stress and inflammation in mucopolysaccharidosis type IVA patients treated with enzyme replacement therapy.
Donida B; Marchetti DP; Biancini GB; Deon M; Manini PR; da Rosa HT; Moura DJ; Saffi J; Bender F; Burin MG; Coitinho AS; Giugliani R; Vargas CR
Biochim Biophys Acta; 2015 May; 1852(5):1012-9. PubMed ID: 25701642
[TBL] [Abstract][Full Text] [Related]
36. Mucopolysaccharidosis IVA: correlation between genotype, phenotype and keratan sulfate levels.
Dũng VC; Tomatsu S; Montaño AM; Gottesman G; Bober MB; Mackenzie W; Maeda M; Mitchell GA; Suzuki Y; Orii T
Mol Genet Metab; 2013; 110(1-2):129-38. PubMed ID: 23876334
[TBL] [Abstract][Full Text] [Related]
37. Enzyme replacement therapy for treating mucopolysaccharidosis type IVA (Morquio A syndrome): effect and limitations.
Tomatsu S; Sawamoto K; Shimada T; Bober MB; Kubaski F; Yasuda E; Mason RW; Khan S; Alméciga-Díaz CJ; Barrera LA; Mackenzie WG; Orii T
Expert Opin Orphan Drugs; 2015 Nov; 3(11):1279-1290. PubMed ID: 26973801
[TBL] [Abstract][Full Text] [Related]
38. Elosulfase alfa.
Haddley K
Drugs Today (Barc); 2014 Jul; 50(7):475-83. PubMed ID: 25101330
[TBL] [Abstract][Full Text] [Related]
39. Hematopoietic stem cell transplantation for Morquio A syndrome.
Yabe H; Tanaka A; Chinen Y; Kato S; Sawamoto K; Yasuda E; Shintaku H; Suzuki Y; Orii T; Tomatsu S
Mol Genet Metab; 2016 Feb; 117(2):84-94. PubMed ID: 26452513
[TBL] [Abstract][Full Text] [Related]
40. Characterization and pharmacokinetic study of recombinant human N-acetylgalactosamine-6-sulfate sulfatase.
Tomatsu S; Montaño AM; Gutierrez M; Grubb JH; Oikawa H; Dung VC; Ohashi A; Nishioka T; Yamada M; Yamada M; Tosaka Y; Trandafirescu GG; Orii T
Mol Genet Metab; 2007 May; 91(1):69-78. PubMed ID: 17336563
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
